T20 (brand name: Fuzeon; generic name: Enfuvirtide) is the only HIV entry inhibitor targeting the HIV-1 envelope glycoprotein (Env) transmembrane subunit gp41 for treatment of HIV/AIDS patients who fail to respond to the RTIs and PIs [3], [4]. This evidence concerns the gene ERVW-1 and AIDS.